newsfilter
← Latest News
GlobeNewswire·

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial